Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXQB5X
|
||||
| Drug Name |
(Z)-1-Naphthalen-2-yl-3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-yl]urea
|
||||
| Synonyms |
CHEMBL1172838
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C30H22N4O2
|
||||
| Canonical SMILES |
O=C(Nc1ccc(cc1)c2ccc3ccccc3c2)Nc4ccc5\\C(=C\\c6ccc[nH]6)\\C(=O)Nc5c4
|
||||
| InChI |
InChI=1S/C30H22N4O2/c35-29-27(17-24-6-3-15-31-24)26-14-13-25(18-28(26)34-29)33-30(36)32-23-11-9-20(10-12-23)22-8-7-19-4-1-2-5-21(19)16-22/h1-18,31H,(H,34,35)(H2,32,33,36)/b27-17-
|
||||
| InChIKey |
JZCBGMAKTMOCFP-PKAZHMFMSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| FL cytokine receptor | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04060:Cytokine-cytokine receptor interaction | |||||
| Hematopoietic cell lineage | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.